[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Bnai Zion Medical Center\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":253},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,49,79,104,134,156,179,205,229],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100620333","oral-iron-in-pregnant-women-how-often-to-take-it-and-its-side-effects-and-tolerability-100620333",false,"NCT07356258","Oral Iron in Pregnant Women: How Often to Take It and Its Side Effects and Tolerability","Iron Supplementation Frequency and Tolerability in Pregnancy","IRONFIT","Inclusion Criteria:\n\n* Pregnant women aged 18-50\n* Indication for oral iron treatment as determined by the treating physician, in accordance with standard clinical practice\n* Baseline iron store levels measured prior to initiation of oral iron therapy\n\nExclusion Criteria:\n\n* Women taking ferrous sulfate 80 mg Tardiferon\n* Gastrointestinal diseases such as colitis\n* Women who received intravenous iron during pregnancy\n* Women who received blood transfusions during pregnancy\n* Women with anemia due to causes other than iron deficiency\n* History of bariatric surgery\n* Allergy to ferrous sulfate","FEMALE","18 Years","50 Years",{"count":21,"type":22},50,"ESTIMATED","OBSERVATIONAL","The goal of this prospective observational study is to examine the frequency of gastrointestinal side effects associated with oral iron supplementation during pregnancy. The main question it aims to answer is:\n\nDoes intermittent oral iron supplementation result in fewer gastrointestinal side effects compared with daily supplementation in pregnant women? Pregnant women who are prescribed oral iron as part of their routine medical care will take ferrous sulfate on an alternate-day schedule for one week. If no significant gastrointestinal side effects are reported, they will then take ferrous sulfate daily for an additional week and will be followed for one month. Participants will be contacted by the study investigator to report gastrointestinal side effects, and routine blood tests will be used to assess changes in hemoglobin and iron stores.",[26,27],"Iron Adverse Reaction","Anemia Complicating Pregnancy",[29,30,31,32,33,34,35],"pregnancy","iron tolerability","oral iron supplementation","ron deficiency anemia","ferrous sulfate","alternate-day dosing","daily dosing","NOT_YET_RECRUITING","2026-01-25",{"date":39,"type":40},"2026-01-27","ACTUAL",{"date":42,"type":22},"2026-02-01",{"date":44,"type":22},"2026-06",{"name":46,"class":47},"Bnai Zion Medical Center","OTHER_GOV",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":58,"phases":59,"briefSummary":61,"conditions":62,"keywords":64,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":48},"100615085","phase-4-topical-anesthesia-during-catheter-insertion-for-cervical-ripening-tolerance-100615085","NCT07288021","Topical Anesthesia During Catheter Insertion for Cervical Ripening (TOLERANCE)","TOLERANCE","Inclusion Criteria:\n\n* Women scheduled for labor induction with balloon catheter.\n* 18 years of age or older.\n* Singleton pregnancy with a cephalic presentation.\n* ≥ 34 completed gestational weeks.\n* Does not participate in any other trial that might affect maternal or fetal\u002Fneonatal outcomes.\n* No contraindication for vaginal delivery\n\nExclusion Criteria:\n\n* Unable or unwilling to provide and sign informed consent forms.\n* Known sensitivity to EMLA or placebo substance.\n* Known vulvodynia or vaginismus - rendering vaginal examination not possible.\n* Any chronic pain syndrome",{"count":57,"type":22},200,"INTERVENTIONAL",[60],"PHASE4","The goal of this RCT is to learn if application of topical anesthetic cream to the perineum and posterior wall of vagina prior to balloon catheter insertion as part of labor induction will reduce pain levels experienced by pregnant individuals.\n\nAll participants are 18 or older, carrying a singleton in vertex position and in need of labor induction, are late-preterm or term (34 weeks gestation and onward) and without contraindication to vaginal delivery.\n\nInvestigators seek to compare pain levels and patient satisfaction between two groups:\n\nNulliparous patients, using EMLA or placebo (randomized, double blinded). Multiparous patients, EMLA or placebo.",[63],"Labor, Induced",[65,66,67,68,69],"induction","balloon catheter","EMLA","Lidocaine\u002Fprilocaine","pain","RECRUITING","2025-12-15",{"date":73,"type":40},"2025-12-17",{"date":75,"type":40},"2024-02-05",{"date":77,"type":22},"2026-07-01",{"name":46,"class":47},{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":4,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":86,"minAge":18,"maxAge":4,"enrollmentInfo":87,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":89,"conditions":90,"keywords":92,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":48},"100590372","nerve-block-treatment-for-chronic-jaw-pain-100590372","NCT06966557","Nerve Block Treatment for Chronic Jaw Pain","Treatment of Chronic Temporomandibular Pain With Peripheral Nerve Block","Inclusion Criteria:\n\n* Adults (non-pregnant) with sound judgment\n* Chronic TMJ pain lasting at least 12 months\n* Documented failure of at least two previous treatment modalities\n\nExclusion Criteria:\n\n* not meeting inclusion criteria\n* Missing at least two follow-up visits within the specified timeframe","ALL",{"count":88,"type":22},40,"Study Summary: Nerve Block Treatment for Chronic Jaw Pain This study is being conducted at the TMJ (temporomandibular joint) clinic, which is part of the oral and maxillofacial surgery department. The goal is to evaluate how effective peripheral nerve blocks are in reducing long-term jaw pain in patients with chronic temporomandibular disorders (TMD) who haven't responded to at least two other types of treatment (such as physical therapy, medication, or bite splints).\n\nWhat Is the Treatment? Peripheral nerve blocks are injections that temporarily block nerve signals from the painful area. This can relieve pain and improve function. These blocks are already used routinely at the clinic.\n\nWho Can Join? Adults who have had jaw joint pain for over a year.\n\nHave tried at least two other treatments without success.\n\nAre mentally competent and not pregnant.\n\nWhat Will Participation Involve? You'll receive the nerve block treatment as part of your regular care.\n\nYou'll be asked to attend follow-up visits, typically one every 4 months (3 per year).\n\nYou'll be monitored for pain relief, mouth opening ability, and use of pain medications.\n\nYou can stop participating at any time without affecting your care.\n\nHow Will Data Be Handled? Your information will be stored securely and coded to protect your identity.\n\nOnly the research team will have access to your personal information.\n\nHow Many People Will Be in the Study? The goal is to recruit 40 patients.",[91],"TMJ Pain",[91,93,94,95],"Nerve block","Peripheral nerve block","Chronic temporomandibular pain","2025-06-09",{"date":98,"type":40},"2025-06-10",{"date":100,"type":40},"2025-04-25",{"date":102,"type":22},"2026-07",{"name":46,"class":47},{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":4,"eligibilityCriteria":110,"healthyVolunteers":11,"sex":86,"minAge":18,"maxAge":4,"enrollmentInfo":111,"targetDuration":4,"studyType":58,"phases":113,"briefSummary":115,"conditions":116,"keywords":118,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":48},"100555681","integrative-therapies-in-multiple-myeloma-100555681","NCT06515249","Integrative Therapies in Multiple Myeloma","Effectiveness and Safety of Integrative Therapies in Multiple Myeloma","Inclusion Criteria:\n\n* Age over 18\n* Diagnosis of multiple myeloma\n* Possibility to answer questionnaires once a month in Hebrew, Arabic or Russian\n* Signing an informed consent form\n\nExclusion Criteria:\n\n* Age under 18 years\n* In patients who will receive acupuncture: platelet level below 20x10\\^9\u002FL\n* In patients who will receive reflexology: deep vein thrombosis in the leg\n* Hemodynamic instability\n* Psychiatric disorder impairing competence",{"count":112,"type":22},300,[114],"NA","Multiple myeloma is a hematologic malignancy that can cause anemia, renal failure, bone disease, and hypercalcemia. Today, myeloma is considered a chronic disease and most patients will receive ongoing biological treatments. As a result, this disease causes a number of symptoms related to the disease itself or its treatment, which include, among others, weakness and fatigue, bone or nerve pain, depression and anxiety, gastrointestinal symptoms, impairment of sexual function, etc. These symptoms cause significant damage to quality-of-life which is similar in patients who receive different treatment lines. As a result, the FDA emphasized quality-of-life as a key outcome for the approval of new drugs for the disease.\n\nThe conventional therapeutic approach to the various symptoms is based on supportive care guidelines including pharmacological and non-pharmacological treatment of pain, gastrointestinal symptoms, psychological components, etc. These treatments involve side effects and usually refer to individual symptoms.\n\nComplementary and integrative medicine includes treatments of touch, movement, mind-body, acupuncture, nutrition and nutritional supplements. Many studies have shown the effectiveness of these treatments on various symptoms in cancer patients including pain, depression and anxiety, fatigue and weakness, gastrointestinal symptoms, etc. In myeloma patients, the effect of diet and nutritional supplements was mainly examined, but there is also little information on the effectiveness of mind-body treatments on symptoms of anxiety and depression, as well as acupuncture on neuropathy or on symptoms experienced by myeloma patients around autologous bone marrow transplantation.\n\nIn recent years, a wide variety of new drugs have entered the market that cause side effects that were unknown until now and little is known about the effect of complementary medicine treatments on symptoms and quality-of-life of myeloma patients since the development of these drugs.\n\nIn this study we will examine the effect of complementary and integrative medicine treatments (including acupuncture, touch, movement, mind-body) on the quality-of-life and symptoms that characterize myeloma patients during treatment with different lines of therapy, including new drugs.\n\nPatients with a diagnosis of multiple myeloma who meet the study\\'s inclusion criteria will be divided into the intervention group (complementary medicine treatments) and the control group (no treatments) according to their preferences. All the patients of the intervention group and the patients of the control group who agree will be asked to fill out quality-of-life questionnaires validated and translated into Hebrew, Arabic and Russian before the start of the treatment. The questionnaires include European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) which is a general quality-of-life questionnaire for cancer patients, with the addition of MY20 which is an addition of 20 specific questions for patients with multiple myeloma, the Edmonton Symptom Assessment System (ESAS) questionnaire which examines the severity of 10 common symptoms in patients with malignant disease, and the EuroQol-5 Dimension (EQ-5D) questionnaire which examines quality-of-life in cancer patients and is used as a primary outcome in many clinical studies. The same questionnaires will be sent again 1-2 weeks after the end of the treatments in the intervention group and 6-8 weeks after recruitment in the control group. Socio-demographic and medical data will also be collected from the patients and their medical records.",[117],"Multiple Myeloma",[117,119,120,121,122,123,124,125],"Integrative Medicine","Quality-of-life","Complementary medicine","Hematology","Acupuncture","Mind-body","Touch","2024-07-17",{"date":128,"type":40},"2024-07-23",{"date":130,"type":40},"2024-07-15",{"date":132,"type":22},"2028-07",{"name":46,"class":47},{"id":135,"slug":136,"hasResults":11,"nctId":137,"briefTitle":138,"officialTitle":139,"acronym":4,"eligibilityCriteria":140,"healthyVolunteers":11,"sex":86,"minAge":18,"maxAge":4,"enrollmentInfo":141,"targetDuration":4,"studyType":58,"phases":143,"briefSummary":145,"conditions":146,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":48},"100555318","phase-3-astragalus-for-symptomatic-alleviation-in-high-grade-lymphoma-100555318","NCT06510530","Astragalus for Symptomatic Alleviation in High-grade Lymphoma","Efficacy and Safety of Astragalus for Symptomatic Alleviation in Patients With High-grade Lymphoma Treated With Chemotherapy: a Double-blind Randomized Placebo-controlled Trial","Inclusion Criteria:\n\n* Age over 18\n* Diagnosis of high-grade lymphoma\n* Need to start treatment for lymphoma that includes chemotherapy as first line\n* Possibility to answer questionnaires once a month\n* Signing an informed consent form\n\nExclusion Criteria:\n\n* Taking up to a week before the randomization a drug with the potential for an interaction of major clinical significance with Astragalus according to a professional database\n* Administration of chemotherapy in the past\n* Significant disturbance in liver enzymes: Aspartate transaminase and\u002For alanine transaminase above 5 times the upper limit of normal\n* Significant renal dysfunction: glomerular filtration rate under 30 ml\u002Fmin according to Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation\n* Active autoimmune disease\n* Pregnancy or breastfeeding\n* Active participation in another interventional study\n* Psychiatric disorder with impaired cognitive qualifications",{"count":142,"type":22},60,[144],"PHASE3","Lymphoma is a malignant disease of the lymph nodes. There are different types of lymphoma: when some of the lymphomas are indolent and require only follow-up, in cases of aggressive lymphoma or indolent lymphoma with a burden of disease, treatment is necessary, which usually includes chemotherapy with or without biological drugs. These drugs often cause significant damage to the quality of life, various symptoms including exhaustion, neuropathic pain, nausea\u002Fvomiting, cognitive decline, as well as a drop in blood counts with serious life-threatening infections that cause a delay in the treatment date that may affect the prognosis.\n\nDrug treatments for symptomatic relief and improvement in quality of life in patients with lymphoma are missing, with only a partial effect and involving side effects.\n\nAstragalus (scientific name: Astragalus membranaceus, common name: Huang Qi) is a perennial flowering plant common in China with a long history of use in traditional Chinese medicine. It is given in various forms of root in combination with other herbs, medicinal soups and as tablets, capsules, solutions, ointments for local use, or subcutaneous or intravenous injection. In patients with oncological diseases, a systematic review (4 trials on a total of 342 patients) showed an improvement in nausea and vomiting as well as in the immune system in patients with colon cancer who received Chemotherapy. A meta-analysis of 27 studies on 1,843 patients with colon cancer also demonstrated a reduction in chemotherapy-induced nausea in patients who received a combination of astragalus with chemotherapy compared to chemotherapy alone. In another meta-analysis that included 45 trials on 3,236 patients with liver cancer, an improvement in 12-month survival was reported with products containing astragalus. In a randomized study of 136 patients with lung cancer, three treatment cycles with astragalus by injection in combination with chemotherapy (vinorelbine and cisplatin) resulted in a significant improvement in quality of life compared to the control group that received chemotherapy alone. Similar results found in 23 patients with metastatic malignancy receiving astragalus by injection in combination with chemotherapy. In addition, a study on 90 patients with advanced cancer showed an improvement in fatigue in patients who received astragalus. Also, a pilot study on 60 patients with breast cancer showed that intravenous administration of astragalus improved blood counts in patients who received it in combination with chemotherapy compared to chemotherapy alone. In patients with hematological malignancies, a study was conducted on 498 patients with acute myeloid leukemia and showed that the use of astragalus or plants containing astragalus was associated with improved survival compared to patients who did not receive it. In the context of lymphoma, a pharmacological study in vivo on animals with lymphoma showed that a combination of an astragalus-containing formula with adriamycin-type chemotherapy improved the effect of adriamycin for the treatment of B-cell lymphoma. Another study in patients who had completed conventional chemotherapy with Rituximab Cyclophosphamide Adriamycine Vincristine Prednisone (R-CHOP) for diffuse large B-cell lymphoma showed that administration of a formula containing astragalus improved immune function and blood counts. Finally, a randomized placebo-controlled study showed that giving a formula containing astragalus to patients under R-CHOP chemo-immunotherapy as first line for diffuse large B cell lymphoma high risk significantly reduced the appearance of side effects from the treatment and improved response to the treatment chemotherapy compared to the control group.\n\nSide effects attributed to astragalus include fatigue, weakness, headaches and hypotension, but in the cited studies and meta-analyses, no increase in the rate of side effects was found in the groups of patients who received this plant compared to the control groups, and no safety problems were described in the use of astragalus in combination with chemotherapy.\n\nIn light of the multitude of symptoms that affect the quality of life and adherence to treatment in patients with lymphoma receiving chemotherapy, and in light of the encouraging findings in the literature about symptomatic improvement as a result of combining astragalus during chemotherapy in various malignancies, the investigators aim to examine the effectiveness and safety of astragalus during the treatment of patients with high-grade lymphoma on symptomatic relief and adherence to chemotherapy in a randomized, double-blind, placebo-controlled study.",[147],"High-grade Lymphoma","2024-07-14",{"date":150,"type":40},"2024-07-19",{"date":152,"type":22},"2024-08",{"date":154,"type":22},"2032-08",{"name":46,"class":47},{"id":157,"slug":158,"hasResults":11,"nctId":159,"briefTitle":160,"officialTitle":161,"acronym":4,"eligibilityCriteria":162,"healthyVolunteers":11,"sex":86,"minAge":4,"maxAge":4,"enrollmentInfo":163,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":165,"conditions":166,"keywords":168,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":171,"lastUpdatePostDateStruct":172,"startDateStruct":174,"completionDateStruct":176,"leadSponsor":178,"locationsCount":4},"100553521","effectivity-gas-extraction-to-prevent-anesthesiologists-waste-gas-exposure-of-sevofluorane-during-pediatric-induction-100553521","NCT06487169","Effectivity Gas Extraction to Prevent Anesthesiologists Waste Gas Exposure of Sevofluorane During Pediatric Induction","Effectivity of the Air Extraction to Prevent Anesthesiologists Waste Anesthetic Gas Exposure of Sevoflurane During Pediatric Induction","Inclusion Criteria: anesthesiologists that work in pediatric anesthesia room performed induction anesthesia with sevoflurane delivery by mask -\n\nExclusion Criteria: anesthesia that required IV induction and that not use sevoflurane\n\n\\-",{"count":164,"type":22},10,"Inhalational anesthetics (IAs) are widely used in surgery and experimental research. IAs, in addition to their medical significance, are a major source of chemical contamination in the operating rooms (ORs).Exposure to IAs in ORs personnel results in reproductive effects, including infertility , spontaneous abortions , congenital diseases , psychological and neurological disturbances, hepatotoxicity , and genotoxicity .The metabolites of sevoflurane include hexafluoroisopropanol (HFIP) and inorganic fluoride (IF). The hospital's engineering department installed an air extractor with the objective to reduce the anesthetic gas concentrations during pediatric anesthesia induction. The investigators are interested in checking if the new technique also has an influence in decreasing the level of Sevoflurane breathed in by the anesthesiologist.The investigators purpose is to detect the presence of desfluoroisopropanolol in the urine of ten anesthesiologists who used sevoflurane to induce children with a mask during an eight-hour session in the induction room (IR) One session will be conducted without the use of the air extractor and the other with the air extractor. After 24 hours, a urine sample will be taken and sent to the Toxicology Unit.",[167],"Unrecognized Condition",[169,170],"sevofluorane,","hexacloroisopropanolol","2024-07-02",{"date":173,"type":40},"2024-07-05",{"date":175,"type":22},"2024-08-01",{"date":177,"type":22},"2025-01-31",{"name":46,"class":47},{"id":180,"slug":181,"hasResults":11,"nctId":182,"briefTitle":183,"officialTitle":184,"acronym":4,"eligibilityCriteria":185,"healthyVolunteers":11,"sex":86,"minAge":18,"maxAge":4,"enrollmentInfo":186,"targetDuration":4,"studyType":58,"phases":188,"briefSummary":189,"conditions":190,"keywords":192,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":198,"lastUpdatePostDateStruct":199,"startDateStruct":201,"completionDateStruct":203,"leadSponsor":204,"locationsCount":48},"100514726","hypnosis-and-virtual-reality-in-bone-marrow-examination-100514726","NCT05982249","Hypnosis and Virtual Reality in Bone Marrow Examination","Effectiveness of Recorded Hypnosis and Virtual Reality in Patients Undergoing a Bone Marrow Examination at the Hematology Unit","Inclusion Criteria:\n\n1. Age 18 or older\n2. Candidate for a BM examination at the hematology unit\n3. Ability to answer questionnaires in Hebrew, Arabic or Russian\n4. Informed consent form signing\n\nExclusion Criteria:\n\n1. Major hearing impairment\n2. Major visual impairment.",{"count":187,"type":22},100,[114],"The goal of this clinical trial is to compare the effects of hypnosis, virtual reality or their combination in patients undergoing a bone marrow procedure.\n\nThe main question it aims to answer is whether such interventions may relieve anxiety and other symptoms described by patients undergoing the procedure.\n\nBefore the bone marrow procedure and after being explained on the study and signing informed consent, the nurse will measure vital signs and participants will fill-out a 2-minutes' questionnaire and will be assigned to one of 3 groups:\n\n* Hearing a 7-minutes hypnotic script via earphones\n* Seeing and hearing virtual images and sounds via a virtual reality device during 7 minutes\n* None of these After these interventions or 10 minutes after assignation for patients not receiving intervention, patients will fill questionnaires again (about 5 minutes for filling the 2 questionnaires) and vital signs will be measured again. Then the bone marrow procedure will be performed. After the bone marrow procedure, the participants will fill-out another 2-minutes questionnaire and vital signs will be measured by the nurse.\n\nResearchers will compare hypnotic script, virtual reality, their combination or none of them to see if they can affect anxiety and other complaints in patients undergoing a bone marrow procedure.",[191],"Hematologic Diseases",[193,194,122,195,196,197],"Bone marrow","Procedure","Hypnosis","Guided imagery","Virtual reality","2024-05-05",{"date":200,"type":40},"2024-05-07",{"date":202,"type":40},"2023-07-13",{"date":102,"type":22},{"name":46,"class":47},{"id":206,"slug":207,"hasResults":11,"nctId":208,"briefTitle":209,"officialTitle":210,"acronym":4,"eligibilityCriteria":211,"healthyVolunteers":11,"sex":86,"minAge":18,"maxAge":4,"enrollmentInfo":212,"targetDuration":4,"studyType":58,"phases":213,"briefSummary":214,"conditions":215,"keywords":216,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":198,"lastUpdatePostDateStruct":223,"startDateStruct":224,"completionDateStruct":226,"leadSponsor":228,"locationsCount":48},"100514727","naturopathic-pharmacological-consultation-in-hematology-100514727","NCT05982262","Naturopathic-pharmacological Consultation in Hematology","Naturopathic-pharmacological Consultation on the Use of Dietary Supplements in Patients With Hematological Diseases","Inclusion Criteria:\n\n1. Followed up for a hematological condition\n2. Ability to fill simple questionnaires in Hebrew, Russian or Arabic\n3. Indication for consultation:\n\n   1. Patient's request to expand knowledge about the use of DHS\n   2. Patient using DHS\n   3. Patient's desire to start using DHS\n   4. Patient that is interested in hearing about the use of DHS for his\u002Fher health condition\n   5. Medical or nursing team's recommendation to take DHS for medical treatment or to improve compliance with conventional treatment.\n\nExclusion Criteria:\n\nNone",{"count":187,"type":22},[114],"The goal of this cross-sectional study is to learn about the effect of a naturopathic-pharmacologic consultation in patients with hematologic conditions. The main question it aims to answer is whether such consultation can improve the safety of dietary and herbal supplements' use among these patients.\n\nParticipants will be asked to answer basic questions and fill-out questionnaire before and after meeting the consultation team. Some patients will be prescribed dietary and herbal supplements that may help relief some of the symptoms they describe, in a safe way and without interacting with the drugs they are taking.",[191],[217,218,122,219,220,221,222],"Dietary supplements","Herbal supplements","Safety","Consultation","Naturopath","Clinical pharmacist",{"date":200,"type":40},{"date":225,"type":40},"2023-06-15",{"date":227,"type":22},"2028-06",{"name":46,"class":47},{"id":230,"slug":231,"hasResults":11,"nctId":232,"briefTitle":233,"officialTitle":234,"acronym":4,"eligibilityCriteria":235,"healthyVolunteers":11,"sex":86,"minAge":18,"maxAge":4,"enrollmentInfo":236,"targetDuration":4,"studyType":58,"phases":238,"briefSummary":239,"conditions":240,"keywords":242,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":247,"lastUpdatePostDateStruct":248,"startDateStruct":250,"completionDateStruct":251,"leadSponsor":252,"locationsCount":48},"100514724","integrative-medicine-in-lymphoma-survivors-100514724","NCT05982223","Integrative Medicine in Lymphoma Survivors","Effectiveness of Integrative Medicine Treatments in Lymphoma Survivors","Inclusion Criteria:\n\n* Patients diagnosed with a lymphoproliferative disease\n* Aged 18 years or older\n* Received chemotherapy, biological treatment or both for treating the lymphoproliferative disease\n* Defined in remission for less than one year by the haemato-oncologist (maintenance therapy is authorized)\n* Can respond to questionnaires\n* Signed informed consent\n\nExclusion Criteria: None",{"count":237,"type":22},90,[114],"Lymphoma is a cancer of the lymph nodes. While some are \"silent\" and only require follow-up, in cases of aggressive lymphoma, treatment is necessary, and usually includes biological drugs, chemotherapy or both. These drugs often cause significant damage to quality-of-life and various symptoms that do not always go away. Although the treatments are often limited in time and with recovery rates over 60%, most patients are left with a significantly impaired quality-of-life and difficulty in returning to their previous life. Many studies, most of which were conducted in breast cancer survivors, show the place of complementary medicine in the recovery process, both in terms of symptom relief and in improving quality-of-life. Few studies have examined the place of complementary and integrative medicine in lymphoma survivors. The purpose of the present study is to examine the effect of integrative treatments (a combination of conventional and complementary medicine) on quality-of-life of lymphoma survivors, on specific symptoms caused by the disease and its treatment, on economic and social aspects, as well as on the course of the disease. At the hematological unit of Bnai Zion Medical Center, Haifa, Israel, patients with lymphoma who have received chemotherapy, biological treatment or both, and have been defined as recovering by the treating hematologist, will be offered a choice of different types of complementary medicine (acupuncture, herbal medicine, mind-body, movement and touch therapies), emotional treatment (conversations with social worker, spiritual guidance), or both, in addition to the medical and nursing care offered to all survivors. Patients who prefer not to come to the clinic for these treatments will be assigned to the control group and will fill out questionnaires only. The duration of the treatments will be six months and follow-up for another two years. The type of treatments the patient will receive will be chosen in coordination between the integrative team and the patient and according to the symptoms. An assessment will be made on the effect of these treatments on quality-of-life of lymphoma survivors (based on questionnaires), including physical, psycho-spiritual and economic aspects, as well as on the course of the disease.",[241],"Lymphoma",[243,244,121,245,246,123,122],"Lymphoma survivors","Integrative medicine","Quality of life","Shiatsu","2023-07-30",{"date":249,"type":40},"2023-08-08",{"date":202,"type":40},{"date":132,"type":22},{"name":46,"class":47},""]